Advertisement

Medication Adherence and Attrition to Biologic Treatment in Rheumatoid Arthritis Patients

      Abstract

      Purpose

      The objectives of this study were to assess medication adherence rate and attrition rate in first-time adalimumab (ADA) or etanercept (ETA) users in rheumatoid arthritis (RA) patients. This study also identified the risk factors associated with nonadherence and treatment abandonment.

      Methods

      This was a retrospective study with a 2-year follow-up. A total 2151 adult RA patients (18 years of age and older) who initiated ADA or ETA treatment in the Kaiser Permanente Southern California health plan between 2002 and 2009 were identified. Among those on treatment in the first year, continuous treatment receipt was determined by having at least 1 medication refill in the second year; otherwise treatment was considered as abandoned. Medication adherence was measured through proportion of days covered (PDC) and compared between patients continuously on treatment and those abandoning treatment. Risk factors of nonadherence (PDC <80%) and treatment abandonment were estimated by a multinomial logistic regression model.

      Findings

      Patients who abandoned treatment had significantly lower PDC (37.3%) and lower average number of refills (5.1) than adherers (PDC = 88.8%; average number of refills = 12.4) and nonadherers (PDC = 53.3%; average refills = 8.2). Age, African Americans (odds ratio [OR], 1.49; 95% CI, 1.03–2.17), corticosteroids use (OR, 0.80; 95% CI, 0.63–0.98), and history of physical/occupational therapy (OR = 0.66; 95% CI, 0.46–0.93) were associated with nonadherence, whereas having a comorbidity (OR, 1.24; 95% CI, 1.01–1.57) was associated with treatment abandonment. The difference in PDC between ADA and ETA was no longer statistically significant after excluding the treatment abandonment group. A higher proportion of ADA users abandoned treatment than ETA users (42.9% vs 32.2%).

      Implications

      Taking into account treatment abandonment when measuring medication adherence in ADA and ETA use in RA patients can provide a fair and clinically meaningful view of patients’ medication-taking behavior.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Medicare Health & Drug Plan Quality and Performance Ratings 2012 Part C & Part D Technical Notes. Centers for Medicare and Medicaid Services. http://www.cms.gov/Medicare/Medicare.html. Accessed July 21, 2012

        • Osterberg L.
        • Blaschke T.
        Adherence to medication.
        N Engl J Med. 2005; 353: 487-497
        • Jackevicius C.A.
        • Mamdani M.
        • Tu J.V.
        Adherence with statin therapy in elderly patients with and without acute coronary syndromes.
        JAMA. 2002; 288: 462-467
      2. National Quality Forum endorses measures to improve medication safety and quality. National Quality Forum 2009. http://www.qualityforum.org/News_And_Resources/Press_Releases/2009/National_Quality_Forum_Endorses_Measures_to_Improve_Medication_Safety_and_Quality.aspx. Accessed November 13, 2009

        • Singh J.A.
        • Holmgren A.R.
        • Noorbaloochi S.
        Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis.
        Arthritis Rheum. 2004; 51: 952-957
      3. Rheumatoid arthritis - adalimumab, etanercept and infliximab: guidance. TA130: National Institute for Health and Clinical Excellence; 2007.

        • Ting G.
        • Schneeweiss S.
        • Scranton R.
        • et al.
        Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study.
        Arthritis Res Ther. 2008; 10: R95
        • Quan H.
        • Sundararajan V.
        • Halfon P.
        • et al.
        Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.
        Med Care. 2005; 43: 1130-1139
        • Benner J.S.
        • Glynn R.J.
        • Mogun H.
        • et al.
        Long-term persistence in use of statin therapy in elderly patients.
        JAMA. 2002; 288: 455-461
        • Li P.
        • Blum M.A.
        • Von Feldt J.
        • et al.
        Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis.
        Value Health. 2010; 13: 805-812
        • Waimann C.A.
        • Marengo M.F.
        • de Achaval S.
        • et al.
        Electronic Monitoring of Oral Therapies in Ethnically Diverse and Economically Disadvantaged Patients With Rheumatoid Arthritis: Consequences of Low Adherence.
        Arthritis & Rheumatism. 2013; 65: 1421-1429